Mirna Therapeutics Secures $34,500,000 Series C Funding Round

  • Feed Type
  • Date
  • Company Name
    Mirna Therapeutics
  • Mailing Address
    2150 Woodward St. Austin, TX 78744
  • Company Description
    Mirna Therapeutics, Inc., traces its lineage back to Ambion, Inc., a privately held company that offered research reagents for RNA analysis. It was at Ambion where Mirna’s miRNA therapeutic research and development program began in 2002 when the first molecular biology tools were developed for studying miRNAs. Ambion scientists started using these tools themselves to compare the miRNA expression patterns of tumor and normal adjacent tissue.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The funding will enable Mirna to advance its lead microRNA-based therapeutic product candidate MRX34 through human proof of concept studies.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Pfizer Venture Investments
  • Venture Investor
    Osage Ventures
  • Venture Investor
    Correlation Ventures

Trending on Xconomy